Acute and chronic effects of lisinopril on renal and systemic hemodynamics in hypertension
β Scribed by J. P. Degaute; M. Leeman; C. Reuse; E. Carlier; A. Schoutens; P. Vandepapeliere
- Publisher
- Springer US
- Year
- 1992
- Tongue
- English
- Weight
- 561 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0920-3206
No coin nor oath required. For personal study only.
β¦ Synopsis
Acute and chronic effects of the converting enzyme inhibitor lisinopril on renal and systemic hemodynamics were studied in 12 patients with mild to moderate essential hypertension. After a washout period, cardiac output (measured by Doppler echography), renal plasma flow, and glomerular filtration rate (measured by isotopic techniques) were determined before and after oral administration of 20 mg lisinopril (visit 1). The same protocol was repeated after 3 months of lisinopril therapy 20 mg once daily (visit 2). Acute administration of lisinopril, both in untreated hypertensive patients (visit 1) and during long-term treatment (visit 2), decreased blood pressure (p < 0.05) and increased renal plasma flow (p < 0.05), while cardiac output and glomerular filtration rate were unchanged. Comparison of baseline parameters between visits 1 and 2 showed that chronic treatment with lisinopril decreased blood pressure and renal vascular resistance and that these effects were still significant 24-hours postdosage. We conclude that lisinopril is an effective antihypertensive agent with favorable renal hemodynamic effects.
π SIMILAR VOLUMES
Thirteen patients with cirrhosis and tense ascites (six with and seven without peripheral edema) underwent 4to 16-liter paracentesis without intravenous "colloid" replacement. Cardiac output increased from 6.6 f 0.7 liters per min at baseline to 8.2 f 0.7 liters per rnin (p c 0.003) 1 hr after large
The effects of verapamil on hepatic and systemic hemodynamics and on liver function were investigated in 10 patients with portal hypertension due to advanced micronodular cirrhosis to verify whether, as it has been suggested, this calcium channel blocker may improve liver function and reduce portal